Gilead Sciences clinical trial pipeline
Data updated daily from ClinicalTrials.gov, last refresh 2026-11-19
What changed in the last 30 days
17 trials changed in the last 30 days: 1 stopped, 7 with notable changes, 9 with minor changes only.
- Stopped: WONDERS1 · Oral Weekly Lepetegravir (Formerly GS-1720) and Lenacapavir Pacfosacil (Formerly GS-4182) Versus Biktarvy · HIV-1 Who Are Virologically Suppressed Trial terminated
- Notable: HERMOSA-2 · KITE-363 · Autoimmune Neurologic Diseases That Did Not Respond to Usual Treatment Primary and study completion pushed from Jun 2029 to Dec 2031
- Notable: ZUMA-24 · Axicabtagene Ciloleucel Given With Steroids · Relapsed Or Refractory Large B-Cell Lymphoma Results posted: Nov 12, 2026
- Minor: GS-2426 · Advanced Solid Tumors Trial sites expanded: 4 → 8 locations
- Minor: GS-0201 Alone and in Combination · Advanced Solid Tumors Trial sites expanded: 8 → 14 locations
- Minor: Denikitug (GS-1811) Given Alone or With Nivolumab or Chemotherapy · Metastatic Gastric, Gastroesophageal Junction (GEJ), and Esophageal Adenocarcinomas Enrollment closed, study ongoing
- Minor: Injectable Regimen of GS-3242 With Lenacapavir Compared to Biktarvy in People New to HIV-1 Treatment Trial sites expanded: 16 → 21 locations
- Minor: GS-3242 in Combination With Lenacapavir Versus Biktarvy in Virologically Suppressed · HIV-1 Trial sites expanded: 55 → 59 locations
- Notable: ARTISTRY-2 · Bictegravir/Lenacapavir Versus Current Therapy · HIV-1 Who Are Successfully Treated With Biktarvy Results posted: Nov 5, 2026
- Minor: NAPISTAR1-01 · FiH Study to Investigate Safety, PK and Efficacy of the NaPi2b ADC TUB-040 · PROC or r/r Adenocarcinoma NSCLC Enrollment increased: 250 → 334 participants
- Minor: PALISADES-1 · KITE-363 or KITE-753 · Relapsed and/or Refractory B-cell Lymphoma Enrollment closed, study ongoing
- Notable: Seladelpar and Cilofexor · Primary Biliary Cholangitis Recruitment opened
- Minor: KITE-753 Versus Axicabtagene Ciloleucel · Relapsed or Refractory Large B-Cell Lymphoma After First-Line Therapy Enrollment closed, study ongoing
- Notable: Substudy-01: A Study of Long-Acting HIV-1 Treatments Taken by Mouth · HIV-1 With Undetectable Virus Levels Recruitment opened
- Notable: Anitocabtagene Autoleucel · Non-Oncology Plasma Cell-Related Diseases Primary and study completion dates pushed to Oct 2028
- Notable: ARTISTRY-1 · Bictegravir/Lenacapavir Versus Current Therapy · HIV-1 Who Are Successfully Treated With a Complicated Regimen Results posted: Oct 21, 2026
- Minor: PROPEL · Implementation Study of Lenacapavir Pre-exposure Prophylaxis for HIV Prevention Trial sites expanded: 39 → 44 locations
- Stopped: terminated, suspended or withdrawn
- Notable: the plan changed
- Minor: routine updates
New trial filings, last 30 days
| First posted | Trial | Phase | Status |
|---|---|---|---|
| 2026-11-03 | NCT07912996 Study to Compare GS-1179 Versus Valacyclovir in HSV-2 Seropositive Participants With… | Phase 2 | Not Yet Recruiting |
| 2026-11-02 | NCT07908446 Study of BIC/LEN FDC Versus Stable Baseline Regimens in Virologically Suppressed People… | Phase 4 | Not Yet Recruiting |
| 2026-10-29 | NCT07903506 To Evaluate Safety and Efficacy of Anitocabtagene Autoleucel Versus Autologous Stem Cell… | Phase 3 | Not Yet Recruiting |
| 2026-10-21 | NCT07887672 A Trial to Evaluate Safety and Efficacy of Anitocabtagene Autoleucel Versus Standard of… | Phase 3 | Not Yet Recruiting |
Active trials by phase
| Phase 1 | 20 | |
| Phase 1/2 | 8 | |
| Phase 2 | 26 | |
| Phase 2/3 | 6 | |
| Phase 3 | 26 | |
| Phase 4 | 2 |
Not charted: 2 active trials with no phase listed on ClinicalTrials.gov (typically behavioural, device, procedure and observational studies).
Disease areas by active trials, top 10 of 28
Breast Cancer (9) · Lung Cancer (9) · Non-Small Cell Lung Cancer (NSCLC) (8) · Non-Hodgkin Lymphoma (7) · Triple-Negative Breast Cancer (7) · Multiple Myeloma (5) · DLBCL (3) · Leukemia (3) · Acute Lymphoblastic Leukemia (ALL) (2) · Bladder Cancer (2)
Get alerts when Gilead Sciences's trials change
Status changes, date slips, and new filings: detected daily, delivered to your inbox.